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The field of mitral valve disease diagnosis and management is rapidly evolving. New understanding of 
pathophysiology and improvements in the adoption of sophisticated multimodality imaging modalities have 
led to early diagnosis and to more complex treatment. The most common cause of mitral regurgitation (MR) 
in the western world is in the primary alteration of the valve, which leads to degenerative leaflet prolapse due 
to chordal elongation or rupture and annular dilatation. Untreated, significant MR has a negative impact 
prognosis, leading to reduction of survival. In the setting of degenerative MR, surgical repair currently 
represents the standard of care. Treatment of asymptomatic patients with severe MR in the Valve Center 
of Excellence, in which successful repair reaches more than 95% and surgical mortality less than 1%, 
symbolizes the direction for the next years. Transcatheter mitral valve repair with different devices, more 
recently the chordal replacement ones, is providing good outcomes and became a therapeutic option in high-
risk patients with degenerative MR. In the future, more advances are expected from further development of 
interventional techniques, careful evaluation and better patient selection. This review will focus on long-term 
surgical outcomes of mitral valve repair with artificial chordae and on the emerging transcatheter chordal 
repair devices as therapeutic options for degenerative MR patients.
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Keynote Lecture Series
Introduction
One of the most common valvular disorders is mitral 
regurgitation (MR), which has a prevalence of 2% in the 
general population and is present in 7% of the population 
75 years of age or older (1,2). The most frequent cause of 
MR in the developed countries is degenerative mitral valve 
(MV) disease, in which there is myxomatous degeneration 
of the MV leaflets, elongation and redundant chordal 
apparatus (3). Thickened redundant leaflets will prolapse 
back into the left atrium causing malcoaptation of leaflet 
edges and subsequent regurgitation (Figure 1). Rupture 
of chordae is not uncommon in older patients with MR, 
which will then cause a further increase in the severity of 
MR because of unsupported segments of the MV leaflets 
(Figure 2). Patients presenting with severe primary MR 
has a negative prognostic impact, which also decreases the 
survival (mortality rate more than 6.3% per year compared 
with the expected survival rate) (4). 
The current standard of care in this setting is surgical 
repair (1). Treatment of asymptomatic patients with severe 
MR in Valve Center of Excellence, in which successful 
repair reaches more than 95% and surgical mortality less 
than 1%, represents the ideal setting to manage this disease 
in the next 5 years. Transcatheter MV devices for chordal 
replacement are emerging therapies with very satisfactory 
outcomes. Interventional techniques, better patient selection 
and intraoperative imaging guidance are certainly expected 
to advance in the near future. In this review, the primary 
focus will be on the surgical outcomes of chordal repair—as 
a conventional method of care—and transcatheter chordal 
repair as an alternative, equivalent therapeutic option. 
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MV anatomy and prevalence of mitral leaflet 
prolapse
 
The MV consists of two leaflets, separated by two 
commissures, a fibrous annulus, a subvalvular apparatus 
with chordae tendineae and two groups of papillary muscles 
attached to the left ventricle (5). The two leaflets are 
connected by chordae tendineae to the anterolateral and to 
the posteromedial papillary muscles. Three different types 
of chordae tendineae can be described: marginal or primary 
chordae (inserted into the free margin of the leaflets), basal 
or secondary chordae (insert near the annular attachment) 
and tertiary chordae (insert into the central part of the 
leaflets). The length of chordae regulates overall chordae 
tension, mitral haemodynamics and the coaptation area of 
the mitral leaflets. It has been shown that the chordae which 
are 10% longer than normal double the chordal tension, but 
do not make the MV incompetent, which proves that even 
minor changes in the length can have significant effects on 
the tension of the chordae.
The prevalence of mitral prolapse is 2–3% and its most 
common complication is MR (6). The most common 
etiology of mitral prolapse derives from the myxomatous 
degeneration, which is an intermediate form of disease 
which ranges from fibroelastic deficiency with limited 
prolapse, to more severe forms of multiple bileaflet prolapse 
with excessive tissue, such as Barlow’s disease (7). A severe 
form is represented by leaflet flail, where no coaptation can 
be detected during systole. Most commonly, the posterior 
leaflet is affected by this condition and is associated with 
torn chordae, or even worse, ruptured papillary muscle.
Preoperative and intraoperative imaging 
guidance
Two-dimensional  and Doppler echocardiography 
have become standard for the assessment of patients 
presenting with degenerative MR. Echocardiography is a 
diagnostic gold standard to identify mitral valve prolapse 
(MVP) with flail leaflet, determination of the severity 
of MR and planning. Transthoracic echocardiography 
(TTE) and transesophageal echocardiography (TEE) 
are complementary imaging methods, with the latter 
fundamental for intraprocedural guidance of these 
transcatheter chordal repairs. Heart multislice computed 
tomography (MSCT) and cardiac magnetic resonance 
imaging (MRI) offer complementary information during 
preoperative planning. MSCT is very useful for those 
therapies targeting the annulus, to evaluate annular 
structure and dimensions, quality and amount of annular 
tissue and its relationship with the left circumflex coronary 
artery. The MRI allows better visualization of the dynamic 
MV anatomy throughout the cardiac cycle, although it has 
no role during MV interventions. It has been proven to be 
a useful tool in both the preoperative and follow-up phase 
with a quantitative assessment of MR severity and its impact 
on left ventricular (LV) volumes and systolic function. In 
the near future, more sophisticated multimodality imaging 
software will shape and improve the management of 
transcatheter mitral repair therapies.
Figure 1 Echo view of a prolapse without flail of the posterior 
mitral leaflet (central segment). The three panels show, from top 
to bottom, the morphologic transoesophageal 2D echo aspect of a 
posterior prolapse, the color-Doppler analysis showing an eccentric 
jet causing severe regurgitation and a 3D en face view from the left 
atrium of the mitral leaflet (with the prolapse of P2).
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Surgical outcomes
Surgical repair is the preferred treatment for patients 
with primary MR and is associated with better outcomes 
than mitral replacement (8-10). MR can usually be 
repaired by either resection of the flail and prolapsing 
leaflet segment or by reconstructive techniques using 
artificial polytetrafluoroethylene (PTFE) chords (11). The 
techniques mainly adopted vary according to the center 
and the preference and/or experience of the surgeons, 
but the principal ones are the Von Oppel and Mohr’s 
“loop technique”, the simple chordae placement with 
atrial side knots and the David’s multiple interdependent 
loop technique (12). Posterior leaflet prolapse is the most 
common pathology, causing severe MR and has higher 
success of durable repair than anterior leaflet disease or 
severe bileaflet disease (13). Artificial chordae with PTFE is 
a popular technique that can enhance the zone of coaptation 
of the MV when compared with leaflet resection, enhancing 
the valve performance. Currently, artificial chordae with 
PTFE is the technique perhaps the most adopted to correct 
anterior leaflet prolapse. Originally described by Frater and 
Zussa, this technique has grown in popularity over the past 
several years (14-17).
Artificial chordae insertion without leaflet resection 
can repair all prolapsing valves, independent of which 
leaflet is involved, and is ideal for minimally invasive 
approaches. One of the advantages of artificial chordae is 
Figure 2 Transesophageal echo view of a prolapse with flail of the posterior mitral leaflet due to chordal rupture. The four-panel image 
depicts, from the top to the bottom and from left to right, the transoesophageal echo of the two mitral leaflets. Morphologic 2D with color-
Doppler analysis show severe mitral regurgitation, with an eccentric jet. The 3D echo, en face view of the mitral leaflets, depicts the chordal 
rupture which is moving free in the left atrium during the systole. Last, the prolapse flail with bulging of the posterior leaflet in the central 
and medial segment can be appreciated in the 2D echo intercommissural morphologic view.
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their versatility, considering that chordae elongation is a 
major cause of MR in degenerative pathology. They can be 
applied to almost any pathology including systolic anterior 
motion (SAM), Barlow’s disease, anterior and posterior 
mitral leaflet pathology, pediatric and adult populations, 
hypertrophic cardiomyopathy and others (12).
One the largest series of patients was described by 
Salvador, reporting an operative mortality of <1% in 
a cohort of 608 patients undergoing MV repairs using 
artificial chordae. Survival was 84% at 15 years (16). 
Similar early mortality rates have been described by other 
series, ranging from 0% to 4.2%. Perier et al. report a 10-
year survival of 84% in a cohort of 225 patients following 
chordae implantation (15). These outcomes have been 
validated by comparison to classical techniques, in both 
children and adults and in robotic approaches. Falk et al. (18) 
compared Carpentier resection with artificial chordae 
insertion (using the “loop technique”) for the repair of 
the MV (see later). Only 2 peri-operative deaths, both 
in the loop group, were reported, without late mortality. 
Seeburger et al. showed that there was 96.6% survival at 
5 years in 317 patients undergoing artificial chordae loop 
insertion (11). 
These results validated artificial chordae mortality 
outcomes as comparable with classical techniques in the 
long term (12). A seminal paper from David et al., reporting 
the results with PTFE chordae repair, showed that MV 
function remains stable in most patients during the first 
twenty years after operation. At 18 years follow-up, the 
freedom from reoperation on the MV was 90.2%±2.4%, the 
freedom from recurrent severe MR was 91.0%±2.7%, while 
the freedom from moderate or severe MR was 67.5%±4.2%. 
Cox regression analysis illustrated that isolated prolapse of 
the anterior leaflet was predictive of MV reoperation. Older 
age, hypertension and LV ejection fraction less than 40% 
were predictive of recurrent moderate or severe MR (19). 
Tabata et al. from Tokyo also reported the long-term results 
of their “tourniquet technique” chordal MV repair (700 
patients with anterior, posterior and bileaflet prolapse). 
Again, the incidence of recurrent MR was higher in the 
anterior leaflet prolapse group, together with absence of an 
annuloplasty ring or band (20).
The biggest issue with chordal repair is adequate length 
determination and fixation during cardioplegic arrest, which 
can be particularly challenging on the anterior leaflet. 
The use of preformed, fixed-length chordae loops may be 
helpful in this regard. As a general rule, it is recommended 
that for posterior prolapse and chordal rupture, artificial 
chordae with a length of 12–14 mm are employed, while for 
the anterior leaflet their length should be 20–22 mm.
Last, the development of artificial chordae techniques, 
accelerated in part due to their proposed applications in the 
setting of minimally invasive MV repair. In this setting, there 
is a large but mixed experience available in literature. Despite 
the heterogeneity of these studies, it is possible to conclude 
that the outcomes with artificial chordae implantation using 
minimally invasive approach offers the same risk and efficacy 
profile of conventional MV surgery (12). 
Transcatheter mitral chordal repair
A great effort has been made in the development of 
catheter-based techniques for mitral chordae repair. This 
method applies all the basic steps of the conventional 
surgery on the beating-heart without the use of the 
cardiopulmonary bypass and follows the established 
doctrine of MV repair “respect rather than resect” (21). The 
first pioneering pre-clinical experiences of transcatheter 
neochordae implantation was performed by Maisano et al., 
in which delivery and adjustment of chordal length, after 
implantation, was done on the beating heart.
By using this feature, the surgeon could correct 
neochordal length under physiologic conditions, on the 
beating heart to reach prolapse correction (22,23). Nowadays, 
there are three devices that enable transcatheter mitral 
chordae implantation. In terms of number of patients treated, 
the first and most known device is the NeoChord System 
(Neochord, Inc., Minnetonka, Minnesota), which received 
the CE Mark in 2013 and is based on a transapical approach. 
Second, the Harpoon Mitral Valve Repair System (H-MVRS, 
Harpoon Medical, Inc., Baltimore, MD, USA), which did not 
receive the CE Mark, but also works transapically. Finally, 
the ChordArt system (CoreMedic, Germany), which is based 
on a fully transcatheter approach (Table 1).
NeoChord DS 1000 (Neochord, USA)
NeoChord DS1000 is based on a solid surgical background 
and its catheter-based technique of implantation of 
neochordae presents an appealing treatment of degenerative 
MR (Figure 3). According to the mode of application, it is 
a minimally invasive system with adjustable PTFE sutures 
(24-26). It is implanted through a small incision on the 
beating heart with the transapical approach. The procedure 
is carried out under echocardiographic guidance. An 
anchor is placed on the leaflet on one side and on the LV 
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myocardium on the other side. Neochordae is then secured 
under the proper tension in order to adjust the artificial 
chordal length. The device obtained the CE Mark in 2012, 
after the initial results were reported in the feasibility 
TACT trial, where an overall reduction of MR to ≤2+ in 
86.7% among 30 patients has been described. So far, the 
device has been used in nearly 1,000 patients.
A multicenter study conducted in Europe showed 
excellent results with the reduction of MR to mild 
or less residual in 96.7% of patients who received 
≥2 neochordae. Further, a 98% survival at 1-year follow-up 
and 84% freedom from major cardiac adverse events were 
observed (26). The complexity of the lesion is clearly 
affecting the reduction of MR. For example, a treatment 
of isolated P2 segment flail or prolapse with NeoChord 
DS 1000, 1-year freedom from MR recurrence, mitral 
surgery, mortality, rehospitalisation and stroke was 94%. 
However, in the presence of more complex anatomy 
(bileaflet or commissural involvement) or treatment of 
multiple posterior leaflet segments with prolapse or flail 
freedom from the composite endpoint was 63% and 82%, 
respectively. There has also been a learning curve effect 
Figure 3  The NeoChord DS 1000 System_ Courtesy of 
NeoChord (NeoChord, USA).
Table 1 Characteristics of the transcatheter mitral valve chord repair devices
Device Advantages Limitations Trial Results 
NeoChord
System
Minimally invasive system Complexity of the lesion is 
affecting the reduction of MR 
and outcomes
TACT trial 30 patients at 7 centers 
Implantation without the use 
of CPB
Residual leaflet prolapse in 
complex anatomy
Multicenter, 
nonrandomized, 
prospective study
At 30 days, 17 patients 
(59%) achieved MR grade 
≤2+0.36
Is carried out under 
echocardiographic guidance 
Long learning curve More than 500 patients 
treated worldwide
Harpoon Mitral Valve 
Repair System
Leaflet anchoring is carried 
out with a preformed knot 
instead of free-edge leaflet 
fixation 
Fixation of the neochord far from 
the free edge of the leaflet
TRACER trial 30 patients at 6 centers 
Smaller introducer sheath on 
the LV apex enables easier 
and repeated access
Residual leaflet prolapse in 
complex anatomy
Multicenter, 
nonrandomized, 
prospective study
At 1 month in 89% of 
patients, MR was mild
At 6 months in 85% of 
patients, mild MR was 
stable
ChordArt Implantation of premeasured 
neochordae 
Residual leaflet prolapse in 
complex anatomy
CHAGALL trial –
Simple anchoring system, 
with which the distal chord 
is applied in its anatomical 
position, directly to the 
papillary muscle
Complexity of the lesion is 
affecting the reduction of MR 
and outcomes
Multi-center, 
nonrandomized, 
prospective study
CPB, cardiopulmonary bypass; MR, mitral regurgitation; LV, left ventricular.
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observed (24).
As the approach with NeoChord is becoming more 
appealing, a need for a better patient selection has arisen 
and even the patients in early stages of MR without annulus 
dilatation have become appropriate candidates for this type 
of the intervention (27).
There is currently an ongoing clinical investigation 
of NeoChord in a randomized trial in the United States, 
“Randomized trial of the NeoChord DS1000 system 
versus open surgical repair” (RECHORD). The greatest 
limitations of the current generation of the device lies in 
its transapical access. The device requires multiple entries 
and exits through the apex and is delivered sheathless. In 
the treatment of multi-segment disease, or when there 
is a need for multiple chordae, there is also an increased 
risk of bleeding. Nevertheless, NeoChord implantation 
has been shown as a safe and feasible procedure that 
shortens the time of operation in comparison to open-heart 
MV repair.
Harpoon TSD-5 (Edwards Lifescience, USA)
In an early feasibility trial in patients with degenerative 
MR and posterior leaflet prolapse, the Harpoon device has 
been investigated (28). The Harpoon TSD-5 (Edwards 
Lifesciences, Irvine, USA) device is a 14F system designed 
for transapical multiple PTFE implantation. Unlike the 
NeoChord procedure, where the surgical approach is 
rather lateral, the apex is reached through a more anterior 
incision, and the device is inserted into the ventricle 
more closely to the left anterior descending coronary 
artery. Selection of the entry site of the left ventricle and 
navigation towards the MV apparatus is performed using a 
biplane view at mid-commissural and long-axis views. After 
identification of the target site on the prolapsing leaflet, 
the device is stabilized by applying gentle pressure on the 
ventricular side of the leaflet with the end effector. Further 
confirmation of the correct position of the device can be 
obtained using the 3D view from both ventricular and atrial 
sides, adopting different levels of ultrasound depth that are 
represented by specific colors. At this point, the device is 
activated by pushing the handle fire button and a specially 
designed 21-gauge needle wrapped with 50 coils of ePTFE 
in a preformed knot configuration perforates the leaflet 
(Figures 4,5). After needle retrieval, a double-helix ePTFE 
knot is formed on the atrial side of the leaflet, securing the 
associated pair of artificial ePTFE chords to the leaflet. The 
major difference from the NeoChord is in the mechanism 
of leaflet engagement. What should be investigated at long-
Figure 4 The Harpoon TSD-5 System_ Courtesy of Harpoon 
(Edwards Lifescience, USA).
Figure 5 The Harpoon TSD-5 System during the different phases of the chordal implantation_ Courtesy of Harpoon (Edwards 
Lifescience, USA).
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term follow-up should be the fixation of chordae far from 
the free edge of the leaflet. 
The results of the initial feasibility trial evaluating 
Harpoon TSD-5 device showed that among 30 patients, 3 
patients required conversion to open mitral surgery. Neither 
major adverse events nor deaths occurred during the study. 
At 1 month in 24 out of 27 patients (89%), MR was mild 
or even smaller and in three out off 27 patients (11%), 
moderate. At 6 months, MR was mild or smaller in 22 out of 
26 patients (85%), moderate in two out of 26 patients (8%) 
and severe in two out of 26 patients (8%). During the 
investigation at 6 months, favourable cardiac remodeling, 
decrease of LV and left atrial (LA) volumes and as well as 
mitral annulus diameter reduction were reported (28).
Crucial patient selection is the critical point to both 
chordal implantation devices. Preferable pathology of the 
MV for a successful and durable repair is a mono-segmental 
pathology, limited LV dilatation and without or with mild 
annular dilatation. Furthermore, what is different from 
the surgical chordal repair is that the distal extremity of 
the PTFE suture is not fixed to the papillary muscles, as 
in native anatomy, but it is fixed to the apical access. The 
consequences of this should be investigated at long-term 
follow-up. 
ChordArt (CoreMedic, Germany)
The ChordArt System has been designed to implant 
premeasured neochordae in order to overcome some of the 
limitations of the previously mentioned devices. Transatrial 
or transseptal antegrade approaches are used to place the 
neochordae. The anchoring system is simple, with which the 
distal chord is applied in its anatomical position, directly to 
the papillary muscle. For this type of therapy, multimodality 
imaging guidance could theoretically play a central role, 
integrating echo- and computed tomography-fluoro fusion 
imaging to determine trajectories and orientation (Figure 
6). With preoperative echo or with CT, the size of the 
B
D
C
E
FA
Figure 6 Intraprocedural guidance with multimodality fusion imaging during preclinical experience with Chordart device, using the 
EchoNavigator®-system (Philips Healthcare, Best, The Netherlands) side-by-side with the HeartNavigator®-system (Philips Healthcare), 
which enables CT planning and CT-fluoroscopy overlay. Using the HeartNavigator, the optimal trajectory of the device from the tip of 
the target papillary muscles through the corresponding MV leaflet, to define the coaxial entry point into the left atrium, was assessed (A). 
Grasping of P2 segment with HeartNavigator (B), EchoNavigator (C) and TEE guidance in real-time. Finally, Chordart implant with 
HeartNavigator (D) and EchoNavigator (E) guidance [F; Leaflet side of Chordart (*) papillary muscle side of Chordart (**)]. MV, mitral 
valve; CT, computed tomography; TEE, transesophageal echocardiography.
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implant can be determined. Preclinical validation has been 
done and first-in-human implants with surgical direct 
implantation of the device has been recently announced, 
reporting good outcomes (29). The Chagall trial will be 
the prospective, multicenter study which will establish the 
safety and the effectiveness of the Chordart system (30).
Role of concomitant annuloplasty to artificial 
chordae
The progress of transcatheter therapies and in particular, 
of the implantation of mitral chordae, is constant and in 
continuous evolution. The major limitation lies in the 
absence of combined treatment of mitral annulus dilatation, 
a condition associated in most patients with degenerative 
mitral pathology. The surgical results of mitral repair 
without annuloplasty are unsatisfactory in the long term and 
the initial experience with NeoChord also disadvantages 
the latter subgroup (26,31). A critical factor is therefore the 
selection and early treatment of the patient in a phase of 
disease in which prolapse and/or flail is still the prevalent 
pathology, whilst in the absence or near-annular dilation. 
Nowadays, early referral allows treating patients with only 
leaflet disease and preserved LV volumes and not dilated 
annuluses, questioning the need for a ring and confirming 
the rationale behind the transcatheter chordal repair alone.
The Leaflet-to-Annulus Index (LAI) <1.4, defined as 
the ratio between the sum of anterior leaflet length and 
posterior leaflet length over antero-posterior length, can 
be used as reliable predictor to identify patients without 
annular dilatation (32,33). The LAI identifies the quantity 
of overlapping leaflet tissue that will represent the 
potential coaptation surface after the correction (Figure 7). 
This excess of leaflet tissue will constitute the potential 
coaptation surface after an effective restoration of the 
posterior leaflet movement, e.g., using the NeoChord 
repair system. In the near future, with increasing clinical 
evidence, improvements in multimodality imaging guidance 
and clearer indications, it will be conceivable to combine in 
most cases the treatment of leaflets (e.g., chordae, edge to 
edge) with direct mitral annuloplasty, whenever the latter is 
needed (34).
Conclusions
In primary MR, surgical repair with artificial chordae, often 
through a minimally invasive approach, provides excellent 
outcomes. Transcatheter mitral chordal devices enabled 
targeted and less invasive repair, providing promising initial 
results. These therapies have the potential to simplify and 
increase the quality and rates of mitral repair and decrease 
the morbidity associated with conventional open cardiac 
mitral operations. As these devices are in the early phases 
of clinical experience, further investigation with longer-
term follow-up and direct comparison with conventional 
MV surgery is necessary to validate the role of transcatheter 
chordae in the armamentarium of multidisciplinary 
valveMV therapies.
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